Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - Rubicon Research Limited, a pharmaceutical formulations company, has filed an addendum to its Draft Red Herring Prospectus (DRHP) with SEBI, updating its financial information for FY25 and the June quarter of FY26 ahead of its planned initial public offering.
The updated financials reveal significant growth, with operating income tripling to ₹1,284.27 crores in FY25 from ₹393.5 crores in FY23, while EBITDA grew six-fold to ₹267.8 crores and profit after tax reached ₹134.3 crores in FY25, compared to a loss of ₹16.8 crores in FY23. The company’s EBITDA margin improved to 20.7%, with return on net worth expanding to 29% in FY25 from negative 5.7% in FY23.
Last week, Rubicon completed a ₹250 crore pre-IPO placement with Amansa Investments Ltd., which reduced promoter General Atlantic’s stake to 54.01% from the 57.34% reported when the company filed its initial DRHP in July 2024. The proposed IPO consists of a fresh issue worth ₹500 crore and an offer-for-sale valued at ₹585 crore.
The company plans to use proceeds from the fresh issue to pay down debt, support inorganic growth through acquisitions, fund strategic initiatives, and for general corporate purposes. In June, Rubicon acquired Alkem Laboratories’ formulations manufacturing facility in Pithampur, Madhya Pradesh, for ₹149 crore in an all-cash deal.
As of June 30, 2025, Rubicon had 81 US FDA-approved products with 70 already commercialized, and maintains two US FDA-inspected R&D facilities in India and Canada, along with two manufacturing facilities in India accredited by multiple regulatory agencies including the USFDA and Health Canada.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.